Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin …

CA Bousman, JM Stevenson… - Clinical …, 2023 - Wiley Online Library
Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta …

F Milosavljević, N Bukvić, Z Pavlović, Č Miljević… - JAMA …, 2021 - jamanetwork.com
Importance Precise estimation of the drug metabolism capacity for individual patients is
crucial for adequate dose personalization. Objective To quantify the difference in the …

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …

JK Hicks, JR Bishop, K Sangkuhl… - Clinical …, 2015 - Wiley Online Library
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major
depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the …

Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review

JR Strawn, L Geracioti, N Rajdev… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: Generalized anxiety disorder (GAD) often begins during adolescence or early
adulthood and persists throughout the lifespan. Randomized controlled trials support the …

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

JMJL Brouwer, M Nijenhuis, B Soree… - European Journal of …, 2022 - nature.com
Abstract The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here,
presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and …

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects

SC Sim, M Kacevska… - The pharmacogenomics …, 2013 - nature.com
Interindividual differences in drug disposition are important causes for adverse drug
reactions and lack of drug response. The majority of phase I and phase II drug-metabolizing …

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19* 17

A Li‐Wan‐Po, T Girard, P Farndon… - British journal of …, 2010 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• CYP2C19 polymorphisms may have
clinical consequences in relation to drugs extensively metabolized by the enzyme.• Recently …

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19

SA Scott, K Sangkuhl, AR Shuldiner… - Pharmacogenetics …, 2012 - journals.lww.com
The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located
within a cluster of cytochrome P450 genes (centromere-CYP2C18-CYP2C19-CYP2C9 …

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

JC Stingl, J Brockmoeller, R Viviani - Molecular psychiatry, 2013 - nature.com
Polymorphic drug-metabolizing enzymes (DMEs) are responsible for the metabolism of the
majority of psychotropic drugs. By explaining a large portion of variability in individual drug …

Citalopram and cannabidiol: in vitro and in vivo evidence of pharmacokinetic interactions relevant to the treatment of anxiety disorders in young people

LL Anderson, PT Doohan, L Oldfield… - Journal of clinical …, 2021 - journals.lww.com
Background Cannabidiol (CBD), a major nonintoxicating constituent of cannabis, exhibits
anxiolytic properties in preclinical and human studies and is of interest as a novel …